Skip to main content
Fig. 1 | Journal of Experimental & Clinical Cancer Research

Fig. 1

From: Targeted inhibition of PDGFRA with avapritinib, markedly enhances lenvatinib efficacy in hepatocellular carcinoma in vitro and in vivo: clinical implications

Fig. 1

CRISPR/Cas9 knockout library screening and transcriptome sequencing identifies PDGFRA as a potential driver of lenvatinib resistance. (A) Workflow of genome-wide CRISPR/Cas9 knockout library screening. (B) The distribution of normalized CRISPR viability scores (lenvatinib treatment versus control) for genes present in the sgRNA library. (C) A flow chart of the Establishment of lenvatinib resistant HCC sublines. (D) Half maximal inhibitory lenvatinib concentration curves of parental (PT) HCC cells and lenvatinib resistant (LR) cells. (E) Volcano plot depicting the differentially expressed protein profiles between PT and LR cells. (F) A Venn diagram illustrating the intersection of genes identified from CRISPR/Cas9 library screening and transcriptomic sequencing results

Back to article page

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

Contact us